Condition
Autoimmune Hemolytic Anemia (AIHA) clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Autoimmune Hemolytic Anemia (AIHA) clinical trials that are recruiting, in China. By phase: Early Phase 1 (2), Phase 1 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest Autoimmune Hemolytic Anemia (AIHA) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| HY001N cell injection for autoimmune hemolytic anemia after failing three or more treatments | Phase 1 | Tianjin | Recruiting | Aug 5, 2026 |
| In vivo CAR-T therapy Arnovie101 for B cell–mediated autoimmune diseases | Early Phase 1 | Beijing, Beijing Municipality | Recruiting | Jun 5, 2026 |
| Orelabrutinib for relapsed or refractory AIHA | Phase 2 | Beijing, Beijing Municipality | Recruiting | Mar 6, 2026 |
| GT801 injection for adults with relapsed/refractory CD19-positive B-cell cancers and autoimmune hemolytic anemia | Early Phase 1 | Zhengzhou, Henan and 1 other locations | Recruiting | Oct 3, 2025 |
| Long-term study of blood diseases in patients in China | — | Tianjin, Tianjin Municipality | Recruiting | Nov 27, 2020 |
All recruiting trials (5)
-
HY001N cell injection for autoimmune hemolytic anemia after failing three or more treatments
This trial tests whether HY001N cell injections are safe and can help adults with autoimmune hemolytic anemia who have not responded to at least three therapies.
-
In vivo CAR-T therapy Arnovie101 for B cell–mediated autoimmune diseases
This open-label, single-arm study tests Arnovie101, an mRNA-LNP-based in vivo CAR-T therapy, in adults with relapsed or refractory SLE or AIHA to see if it is safe and how the body handles it.
-
Orelabrutinib for relapsed or refractory AIHA
This study tests whether taking orelabrutinib by mouth can help adults with relapsed or refractory autoimmune hemolytic anemia (AIHA).
-
GT801 injection for adults with relapsed/refractory CD19-positive B-cell cancers and autoimmune hemolytic anemia
This trial will test whether GT801 injections help adults with CD19-positive B-cell cancers (B-ALL, CLL, B-NHL) or autoimmune hemolytic anemia that have returned or not responded to prior treatments.
-
Long-term study of blood diseases in patients in China
This study is trying to gather detailed information from patients in China with blood diseases like leukemia and multiple myeloma to better understand how these conditions affect their lives and treatment options.
Related topics
Quick answers
How many Autoimmune Hemolytic Anemia (AIHA) clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Early Phase 1: 2, Phase 1: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.